Comparative Pharmacology
Head-to-head clinical analysis: KOVANAZE versus MECLIZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOVANAZE versus MECLIZINE HYDROCHLORIDE.
KOVANAZE vs MECLIZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOVANAZE (norepinephrine and phenylephrine) is a combination of two vasopressors: norepinephrine, an α1-adrenergic receptor agonist with β1-adrenergic activity, and phenylephrine, a selective α1-adrenergic receptor agonist. Both agents cause vasoconstriction and increase blood pressure via activation of α1-adrenergic receptors on vascular smooth muscle.
Meclizine is a histamine H1 receptor antagonist that acts centrally in the vestibular system to suppress nausea and vomiting. It also has anticholinergic and sedative effects.
Intravenous bolus of 1 mg/kg over 10 minutes, followed by intravenous infusion of 0.02 mg/kg/min for 4 hours, then 0.01 mg/kg/min for 20 hours.
25-50 mg orally, 3 to 4 times daily for vertigo; 25-50 mg orally 1 hour before travel, may repeat every 24 hours as needed for motion sickness.
None Documented
None Documented
Terminal elimination half-life: approximately 7-9 hours following nasal administration; clinical significance: supports twice-daily dosing regimen
Terminal elimination half-life: 6 hours (range 5-10 hours). Clinical context: Supports twice-daily dosing; steady-state achieved in approximately 24 hours.
Renal excretion of unchanged drug: ~20-30%; fecal/biliary elimination: minimal (<5%); remainder as metabolites
Renal (unchanged and metabolites): 50%; fecal: 40%; biliary: 10%
Category C
Category A/B
Antihistamine + Corticosteroid Combination
Antihistamine